Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was reduced by Zacks  from a “purchase” rating to a “hold” score in a research note provided to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on finding as well as developing little particle medication candidates to treat cancer cells. The Company‘s products under different phases of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research experts also lately commented on the company. Noble Financial reissued a “buy” rating as well as released a $11.00 price objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also established a “buy” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving typical rate of $2.90 as well as a two-hundred day relocating ordinary price of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping analysts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as an adverse web margin of 8,294.27%. The company had revenue of $0.06 million throughout the quarter, contrasted to the consensus price quote of $0.06 million. During the very same quarter in the prior year, the company uploaded ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will post -1.18 EPS for the current year.

A number of hedge funds have just recently bought and sold shares of ONTX. GSA Resources Partners LLP bought a brand-new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Management LP bought a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP acquired a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional financiers possess 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the recognition as well as development of oncology therapeutics. It concentrates on discovering and also developing small molecule drug prospects to deal with cancer. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

For additional information regarding research offerings from Zacks Investment Research, visit Zacks.com.

This instant information alert was created by narrative scientific research technology and economic data from Market in order to supply viewers with the fastest and also most precise reporting. This tale was examined by Market’s editorial group prior to publication. 



Before you think about Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s top-rated and best performing research experts and the stocks they advise to their customers every day. Market has actually determined the five stocks that top analysts are quietly murmuring to their customers to acquire currently prior to the wider market catches on … and also Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” rating among experts, premier analysts believe these 5 stocks are better acquires.

Comments are closed.